ES2983643T3 - Terapia oral con tridecanoato de testosterona - Google Patents

Terapia oral con tridecanoato de testosterona Download PDF

Info

Publication number
ES2983643T3
ES2983643T3 ES17876230T ES17876230T ES2983643T3 ES 2983643 T3 ES2983643 T3 ES 2983643T3 ES 17876230 T ES17876230 T ES 17876230T ES 17876230 T ES17876230 T ES 17876230T ES 2983643 T3 ES2983643 T3 ES 2983643T3
Authority
ES
Spain
Prior art keywords
testosterone
fixed dose
dose
dosing regimen
daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17876230T
Other languages
English (en)
Spanish (es)
Inventor
Nachiappan Chidambaram
Satish Kumar Nachaegari
Mahesh V Patel
Kilyoung Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipocine Inc
Original Assignee
Lipocine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipocine Inc filed Critical Lipocine Inc
Application granted granted Critical
Publication of ES2983643T3 publication Critical patent/ES2983643T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES17876230T 2016-11-30 2017-11-30 Terapia oral con tridecanoato de testosterona Active ES2983643T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662428167P 2016-11-30 2016-11-30
US201662428317P 2016-11-30 2016-11-30
PCT/US2017/064083 WO2018102618A1 (en) 2016-11-30 2017-11-30 Oral testosterone tridecanoate therapy

Publications (1)

Publication Number Publication Date
ES2983643T3 true ES2983643T3 (es) 2024-10-24

Family

ID=62240656

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17876230T Active ES2983643T3 (es) 2016-11-30 2017-11-30 Terapia oral con tridecanoato de testosterona

Country Status (6)

Country Link
US (6) US20180153905A1 (enExample)
EP (1) EP3548037B1 (enExample)
JP (1) JP2020500864A (enExample)
CA (1) CA3078724A1 (enExample)
ES (1) ES2983643T3 (enExample)
WO (1) WO2018102618A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
JP5887044B2 (ja) 2005-04-15 2016-03-16 クラルス セラピューティクス, インコーポレーテッドClarus Therapeutic, Inc. 疎水性薬物のドラッグデリバリーシステムとその組成物
CA3078724A1 (en) 2016-11-30 2018-06-07 Nachiappan Chidambaram Oral testosterone tridecanoate therapy
WO2020018974A1 (en) * 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
US11931367B2 (en) 2021-09-30 2024-03-19 Lipocine Inc. Oral (17-ß)-3-oxoandrost-4-en-17-yl tridecanoate therapy
US12257257B2 (en) 2023-07-27 2025-03-25 Lipocine, Inc. Testosterone dodecanoate compositions and methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140288039A1 (en) 2009-01-08 2014-09-25 Lipocine Inc. Lipobalanced long chain testosterone prodrugs for oral delivery
US20130225544A1 (en) * 2009-01-08 2013-08-29 Lipocine Inc. Lipobalanced long chain testosterone esters for oral delivery
TW201521731A (zh) 2013-03-15 2015-06-16 利波辛股份有限公司 用於口服之脂平衡的長鏈睪固酮酯
US10245273B2 (en) 2013-12-26 2019-04-02 Clarus Therapeutics, Inc. Oral pharmaceutical products and methods of use combining testosterone esters with hypolipidemic agents
BR112017004127B1 (pt) 2014-08-28 2023-04-11 Lipocine Inc Composição farmacêutica oral
CA3078724A1 (en) * 2016-11-30 2018-06-07 Nachiappan Chidambaram Oral testosterone tridecanoate therapy

Also Published As

Publication number Publication date
US11672807B1 (en) 2023-06-13
US10881670B2 (en) 2021-01-05
US12161651B1 (en) 2024-12-10
EP3548037A1 (en) 2019-10-09
EP3548037B1 (en) 2024-07-03
US20200222426A1 (en) 2020-07-16
CA3078724A1 (en) 2018-06-07
JP2020500864A (ja) 2020-01-16
US11992496B1 (en) 2024-05-28
US12303517B1 (en) 2025-05-20
US20180153905A1 (en) 2018-06-07
WO2018102618A1 (en) 2018-06-07
EP3548037A4 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
ES2983643T3 (es) Terapia oral con tridecanoato de testosterona
JP2020503269A (ja) 経口ウンデカン酸テストステロン療法
ES2688817T3 (es) Formulación en cápsulas solubilizadas de [(1S)-1-{[(2S,4R)-4-(7-cloro-4metoxiisoquinolin-1-iloxi)-2-({(1R,2S)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]carbonil}-2,2-dimetilpropil]carbamato de 1,1-dimetiletilo
US11123351B2 (en) Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime
KR20170020779A (ko) 테스토스테론 운데카노에이트의 안정한 제제
US20240100165A1 (en) Solid snedds based on a specific mixture of acrylic polymers
JP6307711B2 (ja) 経口送達用リポバランス長鎖テストステロンエステル
JP2016514706A5 (enExample)
CN111356450A (zh) Pde5抑制剂的液体填充制剂
RU2779262C2 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ 3α-ЭТИНИЛ-3β-ГИДРОКСИАНДРОСТАН-17-ОНА ОКСИМА
Sravanthi et al. Formulation and evaluation of bi-layer floating tablets of amlodipine besylate and metoprolol succinate
ES2817584T3 (es) Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato